WAGO Annual Meeting

2024 WAGO Annual Meeting

Wednesday, June 12 – Saturday, June 15

Seattle, Washington

Fairmont Olympic Hotel Seattle

Click here for a pdf of the 2024 WAGO Annual Meeting Schedule of Events.

4:00 PM – 7:30 PM

Registration Open

Exhibit & Poster Set-Up

6:00 pm – 7:30 pm

Welcome Reception

Join us for the Welcome Reception to kick-off the 2024 WAGO Annual Meeting at the Fairmont Olympic Hotel – Spanish Foyer.

Step back in time and enjoy the evening reunting with friends in this beautiful hotel that was opened in 1924 and is listed on the National Register of Historic Places!

WAGO is grateful for our commercial support for the Welcome Reception from:

6:30 AM – 8:00 AM

Breakfast

6:30 PM – 12:00 PM

Registration Open

8:00 AM – 8:10 AM

Welcome & Opening Remarks

8:10 AM -9:15 AM

General Session 1

  • 8:10 am – 8:25 am: Readability assessment of Spanish online patient education materials in gynecologic oncology – presented by Dionna Thomas, BA, University of Kansas School of Medicine
  • 8:26 am – 8:41 am: Serum Exosomal E6 and E7 Transcripts in HPV-Positive Cervical Cancer: Potential Biomarkers for Monitoring Disease Progression and Treatment Response – presented by Jill Roberts, MD, University of Miami/Jackson Health System
  • 8:42 am – 8:57 am: An Alternative to Excision: Use of Trichloroacetic Acid for Management of High Grade Cervical Dysplasia in Young Women – presented by Sadhvi Batra, MD, Moffitt Cancer Center
  • 8:58 am – 9:13 am: Assessing the quality of information on HPV and cervical cancer on TikTok – presented by Andrea Alatorre, BS, University of Arizona College of Medicine Phoenix
9:15 AM – 9:30 AM

Break

9:30 AM – 11:05 AM

General Session 2

  • 9:30 am – 9:45 am: Liquid Biopsy Detection of Structural Variant Breakpoints to Monitor Ovarian Cancer Clonal Evolution – presented by Jian Li, MD, PhD, The University of Texas MD Anderson Cancer Center
  • 9:46 am – 10:01 am: RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells – presented by Marwa Aljardali, MD, UT Southwestern Medical Center
  • 10:02 am – 10:17 am: Impact of somatic TP53 mutation type on benefit from bevacizumab in patients with ovarian cancer, a secondary analysis of NRG/GOG-0218 – presented by Kristina Thiel, PhD, University of Iowa
  • 10:18 am – 10:33 am: Does timing matter? Association between time to chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – presented by Sergei Iugai, MD, The Institute for Cancer Care at Mercy
  • 10:34 am – 10:49 am: Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: patient-reported outcomes at diagnosis –
  • 10:50 am – 11:05 am: Granulosa Cell Tumor: Impact of Surgical Route and Tumor Rupture on Recurrence – presented by Erin dwyer, MPH, Department of Obstetrics and Gynecology, University of Washington
11:05 AM – 12:05 PM

Presidential Lecture

Nicholas Tatonetti, PhD, FACMI, Cedars Sinai Medical Center

12:05 PM – 1:50 PM

Industry Supported Symposium

Advanced Strategies in Ovarian Cancers: Exploring emerging therapies and sequencing strategies in accordance with NCCN Guidelines
This program is developed in collaboration between the GOG foundation, Inc. and

 

5:30 PM – 7:00 PM

Networking Event

Join us Thursday, June 13th for the Networking Event at SPIN Seattle where we will come together for a night of connection and ping pong fun!

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Advanced Strategies in Ovarian Cancers: Exploring emerging therapies and sequencing strategies in accordance with NCCN Guidelines, an Industry Supported Symposium during the 2024 WAGO Annual Meeting.

This symposium is developed in collaboration between The GOG Foundation, Inc. and ImmunoGen.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

  • Analyze and apply the National Comprehensive Cancer Network (NCCN) Guidelines to make informed decisions regarding therapies in the competitive ovarian cancer landscape, tailored to individual patient profiles and disease characteristics.
  • Evaluate and construct optimal treatment sequences incorporating MIRV, HER2-targeted therapies, and other modalities, leveraging their synergistic potential to maximize treatment efficacy and patient outcomes.
  • Assess the role of PARP inhibitors (PARPi) in the management of oncological diseases, including considerations for disease progression and implications for subsequent treatment strategies, enabling participants to develop evidence-based approaches for PARPi progression.
  • Demonstrate an understanding of toxicity management, particularly ocular toxicities, and essential testing protocols associated with advanced oncology treatments, equipping participants with the skills necessary to monitor treatment efficacy and mitigate adverse effects effectively.

Moderator


Kathleen Moore, MD

Faculty


Debra Richardson, MD

BJ Rimel, MD

Katherine Fuh, MD, MS, PhD

Agenda

Advanced Strategies in Ovarian Cancers: Exploring emerging therapies and sequencing strategies in accordance with NCCN Guidelines, an Industry Supported Symposium during the 2024 WAGO Annual Meeting

Thursday, June 13, 2024 | 12:20 PM – 1:50 PM PT

12:20 pm – 12:25 pm
Welcome & Introduction
All Faculty
12:25 pm – 12:40 pm
Optimizing Treatment: NCCN Guidelines in the Ovarian Cancer Landscape
Debra Richardson, MD, Stephenson Cancer Center,University of Oklahoma, Oklahoma City, OK, USA
12:40 pm – 12:50 pm
Case Based Presentation
All Faculty
12:50 pm – 1:10 pm
Strategic Sequencing in Oncology: Integrating MIRV, Her2 and Beyond for Optimal Therapeutic Outcomes 
Katherine Fuh, MD, MS, PhD, UCSF Health, San Francisco, CA, USA
1:10 pm – 1:20 pm
Panel Discussion
All Faculty
1:20 pm – 1:30 pm
Toxicity Management Fundamentals: Understanding Ocular Complications and Testing in Gynecologic Oncology Treatment
BJ Rimel, MD, Cedar Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA
1:30 pm – 1:40 pm
PARPi Progression: Navigating Next Steps in Oncology Treatment Strategies
All Faculty
1:40 pm – 1:50 pm
Open Discussion & Closing Comments
All Faculty
6:30 AM – 8:00 AM

Breakfast

6:30 AM – 12:00 PM

Registration Open

7:00 AM – 8:00 AM

Trainee & Early-Career Faculty Session

7:00 AM – 8:00 AM

WAGO Business Meeting

8:15 AM – 9:20 AM

General Session 3

  • 8:15 am – 8:30 am: Timely treatment in locally advanced cervical cancer is influenced by social vulnerability index and insurance type – presented by Jessica Liang, UCSF School of Medicine
  • 8:31 am – 8:46 am: Fragmentation of care is associated with lower rates of receiving guideline concordant treatment in locally advanced cervical cancer – presented by Audrey Mvemba, UCSF School of Medicine
  • 8:47 am – 9:02 am: Predictors of HPV Vaccination in the Postpartum Period for Individuals Aged 18-26 –  presented by Christine Nguyen, MD, Oregon Health & Science University
  • 9:03 am – 9:18 am: Factors associated with fertility sparing management and pregnancy in gynecologic precancer and cancer – presented by Christina Lowry, MD, MA, Kaiser San Francisco
9:20 AM – 9:35 AM

Break

9:35 AM – 10:40 AM

General Session 4

  • 9:35 am – 9:50 am: Patient characteristics associated with aggressive end of life care in California, 2008-2019 – presented by Ross Harrison, MD MPH, Oregon Health & Science University
  • 9:51 am – 10:06 am: Assessment of early-death in gynecologic malignancy among the Commission-on-Cancer facilities – presented by Andrew Vallejo, MD, Univeristy of Southern California
  • 10:07 am – 10:22 am: Evaluating Caregiver Distress: Caring for Those Who Care for Our Patients – presented by Joe Haydamous, MD, McGovern Medical School
  • 10:23 am – 10:38 am: Death with Dignity: Unveiling the Demographics of Medical Aid in Dying (MAID) – presented by Danielle Blemur, MD MPH, Stanford University Obstetrics and Gynecology
10:40 AM – 11:40 AM

Tumor Board

11:55 AM – 1:25 PM

Industry Supported Symposium

Empowering Patients and Providers: A Shared Decision-Making Journey
This program is developed:

 

6:00 PM – 9:00 PM

President’s Reception

Join us for the President’s Reception on Friday, June 14th  at ARELUME Seattle.  Enjoy a night celebrating with sweeping views of the Puget Sound.

WAGO is grateful for our commercial support for the President’s Reception from:

Activity Overview

GSK welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Empowering Patients and Providers: A Shared Decision-Making Journey, an Industry Supported Symposium during the 2024 WAGO Annual Meeting.

This symposium is developed by GSK.

Course Description

The objectives of this presentation are to discuss the burden and unmet needs of gynecologic malignancies, to explore the challenges faced by healthcare providers and by patients, and to highlight current gaps in disease management of gynecological malignancies.  In addition, we will explore patient centricity and shared decision making, including the significance of involving patients in their treatment journey, and highlighting the current and future state of shared decision making in gynecologic malignancies.

6:30 AM – 8:00 AM

Breakfast

6:30 AM – 12:00 PM

Registration Open

6:30 AM – 8:00 AM

Poster Presentations & Exhibit Hall Open

7:00 AM – 8:30 AM

ASCO Update

Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

8:30 AM – 9:35 AM

General Session 5

  • 8:30 am – 8:45 am: AXL inhibition improves the therapeutic efficacy of trastuzumab in uterine serous cancers – presented by Anjali Walia, BS, University of California, San Francisco School of Medicine
  • 8:46 am – 9:01 am: Consideration of PARPi therapy in patients with uterine leiomyosarcoma harboring homologous recombination deficiency repair mutations – presented by Elise Wilson, MD, UC San Diego Health
  • 9:02 am – 9:17 am: Understanding the patient experience on and after mirvetuximab soravtansine in platinum-resistant ovarian cancer – presented by Alexandra Smick, MD, UCLA
  • 9:18 am – 9:33 am: CCL23 reduces expression of CXCL10 in the Ovarian Cancer Tumor Microenvironment as a novel Mechanism of Immuno-Suppression – presented by Susan Lang, MD, Stanford University
9:35 AM – 9:55 AM

Break

9:55 AM – 11:25 AM

General Session 6

  • 9:55 am – 10:05 am: A Needs Assessment of Surgical Learning Gaps in Gynecologic Oncology Fellows at a Single Institution – presented by Yeon Woo Lee, MD, UCSF
  • 10:06 am – 10:21 am: Peri-Operative Outcomes after Gravid Radical Hysterectomy for Treatment of Early-Stage Cervical Cancer – presented by Lydia Makepeace, MD, University of Texas at Southwestern Medical Center
  • 10:22 am – 10:37 am: Novel approaches to managing placenta accreta spectrum: is there an advantage to a longer delay in hysterectomy timing? – presented by Karen Haney, MD, University of Texas Health Science Center
  • 10:38 am – 10:53 am: Increasing Proportion of Adolescent and Young Adult (AYA) Patients Among Gynecologic Malignancies – presented by Christian Pino, MD, University of Southern California
  • 10:54 am – 11:09 am: Exploring Sexual Distress and Surgical Decision-Making in Risk-reducing Gynecologic Surgery – presented by Alisha Othieno, MD, UCSF
  • 11:10 am – 11:25 am: Older cervical cancer patients are inadequately screened prior to diagnosis: an opportunity for improvement – presented by Jaime Kiff, MD, University of Oklahoma Health Sciences Center
11:25 AM – 11:30 AM

Closing Remarks & WAGO 2025 Annual Meeting Location Announcement

WAGO 2025 Annual Meeting
Wednesday, June 18 –  Saturday, 21, 2025